UNSPSC 51272302: Etomidate

This classification denotes an anesthetic agent with the molecular formula C14H16N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z22628B598, chemically known as 1h-imidazole-5-carboxylic acid, 1-((1r)-1-phenylethyl)-, ethyl ester but generally known as etomidate, which bears US NIH Compound Identifier 36339. European Medicines Agency schedules Etomidate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07330MIG. The term ETOMIDATE is an International Non-Proprietary Name.

UNSPSC 51272302 Etomidate is a Commodity code that nominally covers a single pharmaceutical product, yet the recent state and local opportunities tagged under it reveal a broader procurement pattern: state and county health agencies are acquiring pharmaceutical products and related health systems through competitive bidding and cooperative purchasing arrangements. The scope of work under this code in practice spans the purchase of naloxone and drug deactivation systems for community health initiatives, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing networks, and the establishment of direct-to-manufacturer prescription fulfillment programs. Issuing bodies include county health departments (Seminole County, Florida), state health commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP) that serve state and local government facilities across multiple states including Oregon. The code sees activity across Florida, Texas, Minnesota, and Oregon, with cooperative purchasing vehicles serving as a primary acquisition channel for pharmaceutical products.

Recent opportunities include Seminole County's IFB60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023; MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, requiring vendors to supply through three authorized wholesalers and targeting contract effectiveness July 1, 2026; and Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, exploring vendor capabilities for a direct-to-manufacturer prescription program. The Seminole County solicitation requires vendors to manage shipping, delivery, and compliance with E-Verify and drug-free workplace certifications, with potential FEMA funding and a two-year initial term plus one-year renewal option. The MMCAP RFP emphasizes price competitiveness (weighted at 75 percent), EDI capability, cGMP and Drug Supply Chain Security Act compliance, and maintains a two-year contract term with optional extensions through June 30, 2028.